Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Angiogenesis, Metastasis, and the Cellular Microenvironment

Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion

Bin Hu, Keerthi K. Thirtamara-Rajamani, Hosung Sim and Mariano S. Viapiano
Bin Hu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keerthi K. Thirtamara-Rajamani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hosung Sim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariano S. Viapiano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1541-7786.MCR-09-0207 Published November 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Fibulin-3 is specifically upregulated in primary brain tumors. A. Relative expression of fibulin-3 mRNA in solid tumors according to a meta-analysis of microarray data from the Oncomine Research database. Each point is a study that compared a class of solid tumors and their respective control tissue. The t value corresponds to the Student's t test used for comparison in each study; larger absolute t values indicate a greater difference between the two classes compared. Significant (•) and nonsignificant (○) differences at P < 0.05, respectively. Note the consistently upregulated expression of fibulin3 mRNA in primary brain tumors. A list of all studies and the number of control and tumor specimens per study is provided in Supplementary Table S2. B. The mRNA expression levels for the members of the fibulin (FBLN) family were compared in different groups of gliomas versus control brain tissue using microarray data from the NCI Repository for Molecular Brain Neoplasia Data. Columns, mean level of expression for each tumor type or normal brain tissue; bars, SEM. Data for each fibulin member was analyzed by one-way ANOVA followed by post hoc Dunnet's test to compare each type of glioma against controls (*, P < 0.05; **, P < 0.001). Fibulin-3 was consistently upregulated in all types of gliomas analyzed.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Fibulin-3 is highly expressed in glioma tissue and cells. A. Total homogenates from nine high-grade gliomas (two grade 3 astrocytomas and seven grade 3 glioblastomas) and seven age-matched controls were probed for fibulin-3 (arrow). *, nonspecific cross-reactivity of the antibodies used. B. Quantification of results from A; notice that fibulin-3 expression is virtually absent in normal brain compared with gliomas. Integrated optical density (IOD). The accompanying Western blot shows a representative subcellular fractionation of glioma tissue revealing the distribution of fibulin-3. Proliferating cell nuclear antigen, microsomal ribophorin, and soluble α-tubulin were used as specific markers for the nuclei-enriched (N), membrane-enriched (M), and soluble (S) subcellular fractions, respectively. C. Expression of fibulin-3 in the conditioned medium and total lysates of glioma cell lines (U87, U251, and U373), primary cultures of glioma xenografts (X12 and X14), and cultured normal human astrocytes (NHA). Equal protein loading for culture media was determined by protein measurement and by comparable amido black staining of the blot membranes prior to incubation with antibody. D. Analysis of relative migration of fibulin-3 from soluble fraction of glioma tissue (○, tissue) or medium from U251-MG glioma cells (▵, cells) indicated a single form of ∼54 kDa molecular weight, as expected. No other fibulin-3 bands were observed. *, antibody cross-reactivity as indicated above. E. Detection of fibulin-3 mRNA in human glioma cell lines, rodent glioma cell lines (rat CNS-1, mouse GL-261, and KR-158), and NHA. RT-PCR in the absence of template (right). F. Results from qRT-PCR show the comparative expression of fibulin-3 mRNA (columns, mean; bars, SEM) in NHA (control = 1) versus glioma cell lines and glioma neurospheres prepared from patient specimens (OG2, OG6, and OG12) as indicated in Materials and Methods. Gliomaspheres cultured in serum-free conditions express fibulin-3 at levels comparable to those of typical glioma cell lines, suggesting that expression of fibulin-3 in culture is not caused by serum-induced mesenchymal drift.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Fibulin-3 has a predominant isoform in glioma cells. A. Two possible isoforms of human fibulin-3 have been proposed: Fib3L (long, 53-55 kDa) and Fib3S (short, 43-45 kDa). B. Both isoforms were created by PCR, tagged with a COOH-terminal V5 epitope, and expressed in rat CNS-1 glioma cells. Blots were probed with anti-V5 antibody and with antibody against human fibulin-3 that does not cross-react with endogenous rat fibulin-3. Results obtained with both antibodies strongly suggest that recombinant Fib3S is produced much less efficiently than Fib3L and secreted at very low or undetectable amounts to the culture medium. Note that the V5 antibody detected a number of faint bands above the position of Fib3L in the culture medium, which may correspond to glycoforms not detected by the anti–fibulin-3 mAb3-5 antibody.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Expression of fibulin-3 increases substrate-dependent glioma cell adhesion. A. Human (U87MG and U251MG) and rat (CNS-1) glioma cells stably overexpressing fibulin-3 were plated and quantified on multiwell plates coated with fibronectin (FN), type I laminin (LN), high–molecular weight hyaluronic acid (HA), or left uncoated and blocked with bovine albumin (BSA). B. Nontransfected cells were plated as above on multiwell plates coated with purified fibulin-3 (white columns) or left uncoated (BSA, black columns). Fibulin-3 did not act as a proadhesive substrate for any of the cell lines tested. All experiments were repeated at least thrice with three to six replicates per condition. Data (columns, mean; bars, SEM) were analyzed by two-way ANOVA (***, P < 0.001). Results on poly-l-lysine–coated wells were undistinguishable from those on uncoated surfaces (data not shown). C. Relative expression levels of fibulin-3 in conditioned medium from control and fibulin-3–overexpressing U87MG and U251MG glioma cells were determined by Western blotting and confirmed to be within the physiologic range observed in clinical specimens, as described in Materials and Methods. Overexpression of fibulin-3 in transfected rat CNS-1 cells was quantified by qRT-PCR (data not shown) and found comparable with mRNA overexpression levels in transfected human glioma cells.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Fibulin-3 enhances radial glioma cell dispersion and individual cell migration. A. Representative image of control and fibulin-3–expressing cell aggregates (CNS-1 cells) seeded on brain slices and cultured for 5 d (bars, 200 μm). B. The dispersion of the invasive cell lines CNS-1 and X12 on brain slices was analyzed by two-way ANOVA for repeated measures followed by post hoc Bonferroni's test (**, P < 0.01; ***, P < 0.001). Area ratio = area occupied by cells at each time point relative to the original area (points, mean; bars, SEM). C. Semiautomated tracking of CNS-1 cells was used to calculate mean cell velocity (average of frame-to-frame velocity for each cell) and net migrated distance (net difference in cell position between first and last frame). Representative tracks of individual cells imaged overnight. Mean cell velocities remained stable but showed a trend to increase toward the end of the cell-tracking experiment, probably due to cumulative tissue disruption by migrating cells (bar, 200 μm).

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Knockdown of fibulin-3 reduces glioma cell adhesion and motility. A. Reduction of fibulin-3 in the conditioned medium of the cell line U87MG after transient transfection with two independent siRNA sequences. Housekeeping control proteins were quantified in cell lysates. Total protein content was 15 μg/lane in all cases; samples were processed 48 h after transfection. B. Knockdown of fibulin-3 in the cell line CNS-1, monitored by qRT-PCR, following the same procedure as in A. C. Transient knockdown of fibulin-3 reduces cell adhesion to all substrates tested. Transfected cells were analyzed as indicated in Fig. 4. Black columns, control siRNA; white columns, fibulin-3 siRNA (***, P < 0.001 by two-way ANOVA). Results were virtually identical with the cell line U251MG (data not shown). D. CNS-1 cells were transiently transfected with fibulin-3 siRNAs 48 h before seeding on cultured brain slices. Follow-up over 5 d, as indicated in Fig. 5, showed a significant reduction in the total area occupied by dispersed cells (*, P < 0.025, ***, P < 0.001 by two-way ANOVA for repeated measures).

  • FIGURE 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 7.

    Fibulin-3 increases tumor dispersion in vivo. A. Representative control and fibulin-3–overexpressing tumors 15 d after intracranial injection of CNS-1 cells revealed by Nissl staining (top images) or detection of GFP-fluorescent tumor cells (bottom images; bar, 1 mm). Fibulin-3 tumors are larger and less compact than controls. B. Higher magnification of Nissl-stained tumors. Fibulin-3–overexpressing tumors show more diffuse borders and large clusters separated from the tumor mass (bar, 200 μm). C. Tumor area (in mm2) was quantified every fourth section and plotted against the rostrocaudal extension of the tumor, centered on the injection site. Notice the increase in caudal invasion of fibulin-3–expressing tumors, probably due to invasion of thalamoreticular tracts. D. Cell clusters were counted and measured every fourth section as described (61) and their cumulative area quantified using image analysis software (***, P < 0.001 by Student's t test). E. Total tumor volumes were calculated using Cavalieri's estimator of morphometric volume and compared by Student's t test (**, P < 0.01).

  • FIGURE 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 8.

    Expression of fibulin-3 does not affect cell proliferation. A. Representative staining for the proliferation marker Ki67 around the core of control or fibulin-3–overexpressing tumors formed by CNS-1 cells. The proliferative index (percentage of Ki67-positive nuclei relative to total number of 4′,6-diamino-2-phenylindole–stained nuclei in each field; columns, mean; bars, SEM) was calculated by automated scoring of at least 300 nuclei per field (using ImageJ software) and compared by Student's t test (P = 0.228, no significant differences). Note the higher cell density in control tumors (bars, 50 μm). B. Proliferation rates of CNS-1 cells stably transduced with fibulin-3 (•) or a control (○) cDNA were analyzed using a metabolic assay for reduction of tetrazolium. Proliferation curves were repeated twice using triplicates for each day. The absence of significant differences was verified in a second glioma cell line (U251MG).

  • FIGURE 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 9.

    Fibulin-3 promotes metalloprotease expression and activity. A. Tumor tissue (microdissected from the brain) and contralateral, normal tissue from three control and three fibulin-3–expressing CNS-1 tumors were individually collected and processed for qRT-PCR. mRNA expression for the metalloproteases MMP-2, MMP-9, ADAMTS-4 (ATS4), and ADAMTS-5 (ATS5) was compared in each tumor tissue to its contralateral control. Columns, mean log 2 ratio of tumor to normal brain expression; bars, SEM. B. Expression of the same metalloproteases was also compared by qRT-PCR in cultured control (baseline expression = 1) and fibulin-3–overexpressing CNS-1 cells. GAPDH was used as an internal normalizing control in all cases (***, P < 0.001; **, P < 0.01; *, P < 0.025, by two-way ANOVA). C. Increased expression and activity of metalloproteases in the medium of transfected CNS-1 cells was verified by Western blotting for MMP-2 and MMP-9, and by gelatin-zymography. Total amount of protein and detection of serum albumin (BSA, external reference) in the conditioned medium were used as normalization controls to calculate relative MMP expression and activity (20). Analysis of proteoglycan cleavage in these cells also suggested increased activity of the proteoglycan-degrading protease ADAMTS-5 (B. Hu and M.S. Viapiano, unpublished observations).

Additional Files

  • Figures
  • S

    Files in this Data Supplement:

    • Supplementary Data
PreviousNext
Back to top
Molecular Cancer Research: 7 (11)
November 2009
Volume 7, Issue 11
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion
Bin Hu, Keerthi K. Thirtamara-Rajamani, Hosung Sim and Mariano S. Viapiano
Mol Cancer Res November 1 2009 (7) (11) 1756-1770; DOI: 10.1158/1541-7786.MCR-09-0207

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion
Bin Hu, Keerthi K. Thirtamara-Rajamani, Hosung Sim and Mariano S. Viapiano
Mol Cancer Res November 1 2009 (7) (11) 1756-1770; DOI: 10.1158/1541-7786.MCR-09-0207
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Breast Stroma Instability
  • PRSS3/Mesotrypsin in Prostate Cancer
  • MUC1 Drives c-Met–Dependent Migration and Scattering
Show more Angiogenesis, Metastasis, and the Cellular Microenvironment
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement